Dawn Meacham, DO
Family Medicine · Madison, INNPI 1912276866
Payments from drug & device makers
Across 23 payments — averaging $37.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$514
- AbbVie$208
- Novo Nordisk$46
- Lilly USA, LLC$39
- E.r. Squibb & Sons, L.L.C.$32
- Genentech USA, Inc.$18
What the payments were for
- Food & beverage$31036%
- Education$54664%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $514 |
| AbbVie(2 entities) | 13 | $208 |
| Novo Nordisk | 1 | $46 |
| Lilly USA, LLC | 1 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Genentech USA, Inc. | 1 | $18 |
How this compares
$856 in reported general payments places this provider in the 55th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 295 | $147,487 |
| AustedoDeutetrabenazine | 31 | $123,292 |
| OzempicSemaglutide | 132 | $119,917 |
| IngrezzaValbenazine Tosylate | 23 | $86,126 |
| Tetrabenazine | 72 | $80,205 |
| MounjaroTirzepatide | 70 | $74,431 |
| FarxigaDapagliflozin Propanediol | 77 | $51,246 |
| MyrbetriqMirabegron | 137 | $43,045 |
| NamzaricMemantine Hcl/Donepezil Hcl | 114 | $33,625 |
| RexultiBrexpiprazole | 32 | $32,369 |
| JardianceEmpagliflozin | 29 | $20,616 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $20,504 |
| VraylarCariprazine Hcl | 13 | $18,494 |
| Risperdal ConstaRisperidone Microspheres | 17 | $16,671 |
| TrulicityDulaglutide | 16 | $16,459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $514 | $123,29231 claims |
| Novo NordiskOzempic | $46 | $119,917132 claims |
| Lilly USA, LLCMounjaro, Trulicity | $39 | $90,89086 claims |
| AbbVieNamzaric, Vraylar, Linzess | $208 | $60,069139 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Madison
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.